My back of the envelope calculations suggest we have more than enough funds for stage 2 of phase 3 based off the quarterly reporting over the months that include stage 1
of the phase 3.
Those quarterly reports were on Ave 20 million burn, BUT included the MPS 6 trial (now finished) and the 008 trial (now finished and other preclinical studies for adrenal and protocol review meetings.
Also, if you take the time to look at the primary outcome for phase 3 trial, of pain and function at day 56 we were statistically significant in 005 and 008
2mg dose will be fine….
My back of the envelope calculations suggest we have more than...
-
- There are more pages in this discussion • 440 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $216.0K | 1.057M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 143324 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 44935 | 3 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |